Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
STXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.66 - $3.29
Previous CloseN/A
Volume282.58K
Average Volume (3M)437.34K
Market Cap
$174.54M
Enterprise Value$175.61M
Total Cash (Recent Filing)$9.04M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 13, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding84,729,510
10 Day Avg. Volume510,329
30 Day Avg. Volume437,344
Standard Deviation0.18
R-Squared0.20
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.94
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.82
Enterprise Value/Ebitda-8.16
Forecast
1Y Price Target
$4.67Price Target Upside140.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Stereotaxis News
PremiumCompany Announcements
Stereotaxis Reports Strong Revenue Growth and Strategic Milestones
PremiumCompany Announcements
Stereotaxis Earnings Call: Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Financial HealthSTXS likely ended 2024 with approximately $12M in cash and no debt, which could allow for the commercialization of its next-generation product ecosystem and reach profitability without additional financing.
Market ExpansionChina has around 1K hospitals that could adopt STXS's technology, creating optimism about the upcoming China rollout by partner MicroPort.
Regulatory ApprovalsThe approval of the Magbot catheter in China is another key win, ahead of what should be a big year for STXS in 2025.
Bears Say
Regulatory DelaysSTXS anticipates a regulatory submission for the HD mapping catheter could be completed in early 2025.
---
Ownership Overview
22.94% Insiders
6.64% Mutual Funds
32.85% Other Institutional Investors
31.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.66 and its highest was $3.29 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $174.54M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is May 13, 2025 which is in 70 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Mar 03, 2025. The company reported -$0.045 earnings per share for the quarter, beating the consensus estimate of -$0.065 by $0.02.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 84,729,510 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.045 in its last earnings report, beating expectations of -$0.065. Following the earnings report the stock price went down -5.825%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
---
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (140.72% Upside)
$4.67 (140.72% Upside)
Blogger Sentiment
Bullish
STXS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.14%
12-Months-Change
Fundamentals
Return on Equity
-144.19%
Trailing 12-Months
Asset Growth
11.49%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. engages in the design, manufacture, and market of robotic systems and instruments that electrophysiologists use for the treatment of abnormal heart rhythms known as cardiac arrhythmias. Its products include The Epoch Solution, Niobe Magnetic Navigation System, Vdrive Robotic Navigation System, and Odyssey Solution. The company was founded in June 1990 and is headquartered in St. Louis, MO.
---
STXS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Stereotaxis demonstrated strong revenue growth and made significant progress with FDA submissions and strategic acquisitions, which are expected to drive future growth. However, system revenue showed a slight decline, and recurring revenue faced challenges due to external dependencies. The company also reported a higher operating loss and commercial uncertainties in China. Overall, the call presents a balanced picture with potential for future growth tempered by current financial and market challenges.Read More>---
STXS Stock 12 Month Forecast
Average Price Target
$4.67
▲(140.72% Upside)
Technical Analysis
Best Analysts Covering STXS
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-12.17%
reiterated a buy rating last month
Copying Josh Jennings's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -12.17% per trade.
---